Ascentage Pharma Group (AAPG) reported a 2024 loss Thursday of 1.34 renminbi ($0.18) per diluted share, narrower than a loss of 3.28 renminbi a year earlier.
Revenue for the year ended Dec. 31 was 980.7 million renminbi compared with 222 million renminbi a year earlier.
Analyst estimates were not available for comparison.
As of Dec. 31, 2024, cash and bank balances were 1.26 billion renminbi, compared to 1.09 billion renminbi a year earlier.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.